Abstract

Background: Migraine is an acute non-communicable psychiatric disease, which causes many problems for affected patients, creating defects in the life process of these individuals. This complication is often collaborative, and treatment of the participated member can be an effective step to overcome the disturbances of migraines. This study aimed to evaluate the effect of atrifel on patients with migraine headaches associated with gastrointestinal symptoms. Materials and Methods: This double blind randomized clinical trial was conducted on 124 patients, August 2017 till July 2018, who referred to Neurology Clinic of Shahid Sadoughi Hospital, Yazd, Iran. Patients were randomly and equally divided into control and intervention groups. While subjects of the control group received a daily dose of sodium valproate 200 mg, the participants of the intervention group received both the mentioned tablet and atrifel sagir 50 mg pill before lunch and dinner. The relevant parameters were measured before and eight weeks after the intervention. Results: In this research, stress, fatigue, overeating, hearing loud voices, insomnia and consumption of high-calorie foods were more involved in the emergence of migraine, compared to other factors. According to the results, the integrated use of atrifel sagir and sodium valproate significantly reduced the severity of pain, duration of headache and the time required for rest (P<0.001). Conclusion: According to the results of the study, atrifel sagir along with sodium valproate had considerable impacts on reduction of severity of pain, duration of headache and time required for rest in patients.